PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease
PLOS Neglected Tropical Diseases · 2026
DOI: 10.1371/journal.pntd.0014483 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2026. Verfasst von Ayinula Tuohetali und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Pharmacy, The First Affiliat…. Hauptthemen laut MEDLINE: Echinococcosis, Hepatic, Lactic Acid, Anthelmintics, Polyglycolic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Programme of Xinjiang Uygur Autonomous Region, “Tianshan Talent” Program for Training High-level Talents in Medicine and Healthcare, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund.
Abstract (Originalsprache)
Harmine (HM), a bioactive alkaloid, exhibits remarkable antiparasitic potency. Nevertheless, its translational potential is substantially constrained by neurotoxicity, necessitating the development of safer analogs. H-2-168, a rationally designed derivative synthesized via targeted structural modifications of the HM core, has emerged as a leading candidate for further therapeutic exploration due to its favorable pharmacological profile. To optimize its pharmacokinetic properties and enhance treatment efficacy, this study reports the fabrication of H-2-168-loaded poly (lactic - co - glycolic acid) (PLGA) nanoparticles (H8-PLGA-NPs). Results demonstrated that H8-PLGA-NPs exhibited uniform spherical morphology with an average diameter of 198 nm (PDI = 0.15) and a high drug encapsulation efficiency of 88.6%. Following 30-day oral administration (100 mg/kg/day), H8-PLGA-NPs demonstrated significantly enhanced anthelmintic efficacy and tissue regenerative capacity compared to free H-2-168, while effectively ameliorating inflammatory responses and hepatic fibrosis progression. Notably, systemic toxicity was substantially reduced, particularly hepatotoxicity and cytotoxicity. This study substantiates that PLGA-based nanocarriers markedly improve the therapeutic outcomes of H-2-168 against cystic echinococcosis (CE) through optimized drug encapsulation and delivery efficiency, thereby proposing a promising therapeutic strategy for CE management. Nevertheless, comprehensive investigations into the long-term biosafety profiles of these nanoparticles and optimal dosing regimens warrant further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
- College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, China.
- Department of Abdominal Surgery, The Third People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
- Clinical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
ORCID-Profile: Huijing Gao
Förderung
- Key R&D Programme of Xinjiang Uygur Autonomous Region
- “Tianshan Talent” Program for Training High-level Talents in Medicine and Healthcare
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund
- 2023 Clinical Pharmacy Research Fund of Chinese Society of Clinical Pharmacy, China International Medical Exchange Foundation
- Research Fund of Xinjiang Uygur Autonomous Region Pharmaceutical Association
- Xinjiang Agricultural University Graduate Research and Innovation Fund
Zitieren
APA
Tuohetali, A., Chen, B., Xu, Q., Zhu, J., Zhang, Z., Chen, X., Ma, Y., Kuerban, K., Aimulajiang, K., & Gao, H. (2026). PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0014483
Vancouver
Tuohetali A, Chen B, Xu Q, Zhu J, Zhang Z, Chen X, et al. PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease. PLOS Neglected Tropical Diseases. 2026. doi:10.1371/journal.pntd.0014483
BibTeX
@article{Tuohetali2026,
author = {Tuohetali, Ayinula and Chen, Bei and Xu, Qinwei and Zhu, Jiang and Zhang, Zhenping and Chen, Xia and Ma, Yixueying and Kuerban, Kadierya and Aimulajiang, Kalibixiati and Gao, Huijing},
title = {PLGA - encapsulated harmine derivative H-2-168: A promising therapeutic agent for mitigating liver damage in hepatic hydatid disease},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
doi = {10.1371/journal.pntd.0014483}
}
EUVIMED